Revumenib
Revumenib[edit | edit source]
Revumenib is a novel therapeutic agent under investigation for the treatment of certain types of leukemia, particularly those characterized by specific genetic mutations. It is a small molecule inhibitor that targets the menin-MLL interaction, which is crucial in the pathogenesis of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with MLL rearrangements.
Mechanism of Action[edit | edit source]
Revumenib functions by inhibiting the interaction between menin, a protein that plays a role in gene expression regulation, and the mixed-lineage leukemia (MLL) protein. The MLL protein, when fused with other genes due to chromosomal translocations, leads to the development of aggressive leukemias. By disrupting the menin-MLL interaction, revumenib aims to halt the aberrant gene expression that drives leukemia cell proliferation.
Clinical Development[edit | edit source]
Revumenib is currently being evaluated in clinical trials for its efficacy and safety in patients with MLL-rearranged leukemias. Early-phase trials have shown promising results, with some patients achieving complete remission. Ongoing studies are focused on determining the optimal dosing, potential side effects, and long-term outcomes of revumenib treatment.
Potential Side Effects[edit | edit source]
As with many targeted therapies, revumenib may cause side effects, which can vary in severity. Commonly reported adverse effects include fatigue, nausea, and hematological abnormalities such as neutropenia and thrombocytopenia. Monitoring and managing these side effects are crucial components of patient care during treatment.
Future Directions[edit | edit source]
Research is ongoing to explore the full potential of revumenib in combination with other therapeutic agents. Combination therapies may enhance its efficacy and overcome resistance mechanisms. Additionally, studies are investigating its use in other malignancies where the menin-MLL interaction plays a role.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
